Cellular Technical Services Company, Inc.
| |
|
|
| |
OMB APPROVAL |
|
| |
OMB Number: 3235-0145 |
|
| |
Expires: February 28, 2009
|
|
| |
Estimated average burden hours per response...14.5 |
|
| |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
CELLULAR TECHNICAL SERVICES COMPANY, INC.
(Name of Issuer)
Common Stock, par value $.001 per share
(Title of Class of Securities)
(CUSIP Number)
Steven D. Rabin
4400 Biscayne Boulevard
Maimi, Florida 33137
Telephone: (305) 575-6015
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on
the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| |
|
|
|
|
|
|
|
|
|
|
CUSIP No. |
|
151167103 |
|
Page |
|
2 |
|
of |
|
6 |
| |
|
|
|
|
|
| 1 |
|
NAMES OF REPORTING PERSONS
Dr. Charles Filipi |
| |
|
|
| |
|
|
| 2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
| |
(a) o |
| |
(b) þ |
| |
|
|
| 3 |
|
SEC USE ONLY |
| |
|
| |
|
| |
|
|
| 4 |
|
SOURCE OF FUNDS (SEE INSTRUCTIONS) |
| |
|
| |
OO |
| |
|
|
| 5 |
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |
| |
|
| |
o |
| |
|
|
| 6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION |
| |
|
| |
United States of America
|
| |
|
|
|
| |
7 |
|
SOLE VOTING POWER |
| |
|
|
| NUMBER OF |
|
2,814,092 |
| |
|
|
|
| SHARES |
8 |
|
SHARED VOTING POWER |
| BENEFICIALLY |
|
|
| OWNED BY |
|
0 |
| |
|
|
|
| EACH |
9 |
|
SOLE DISPOSITIVE POWER |
| REPORTING |
|
|
| PERSON |
|
2,814,092 |
| |
|
|
|
| WITH |
10 |
|
SHARED DISPOSITIVE POWER |
| |
|
|
| |
|
0 |
| |
|
|
| 11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| |
|
| |
2,814,092 |
| |
|
|
| 12 |
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |
| |
|
| |
o
|
| |
|
|
| 13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |
| |
|
| |
17.5% |
| |
|
|
| 14 |
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| |
|
| |
IN |
| |
|
|
|
|
|
|
|
|
|
|
CUSIP No. |
|
151167103 |
|
Page |
|
3 |
|
of |
|
6 |
ITEM 1. Security and Issuer
This Schedule 13D (this “13D”) is filed with respect to the Common Stock, $.001 par value
(the “Shares”), of Cellular Technical Services Company, Inc., a Delaware corporation (the
“Issuer”). The principal executive offices of the Issuer are located at 4400 Biscayne Boulevard,
Suite 1500, Miami, Florida 33137.
ITEM 2. Identity and Background
(a) This 13D is filed by Dr. Charles Filipi (the “Reporting Person”).
(b) The Reporting Person’s address is 12370 Rose Lane, Omaha, Nebraska 68154.
(c) The Reporting Person’s principal occupation is Professor of Surgery in the Department of
Surgery at Creighton University School of Medicine in Omaha, Nebraska.
(d) To the best of the Reporting Person’s knowledge, such person has not been convicted in a
criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) To the best of the Reporting Person’s knowledge, such person has not, within the last five
years, been a party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final
order enjoining future violations of, or prohibiting or mandating activities subject to, federal or
state securities laws or finding any violation with respect to such laws.
(f) The Reporting Person is a citizen of the United States of America.
ITEM 3. Source and Amount of Funds or Other Consideration.
On September 4, 2007 (the “Closing Date”), the Reporting Person acquired 2,814,092 Shares
(the “Exchange Shares”) upon the consummation of the transactions (the “Transactions”) contemplated
by that certain Share Contribution and Exchange Agreement (the “Exchange Agreement”), dated as of
July 25, 2007, by and among the Issuer, SafeStitch LLC (“SafeStitch”) and the members of SafeStitch
LLC (the “SafeStitch Members”), pursuant to which the Issuer acquired 100% of the SafeStitch
Members’ membership interests in SafeStitch. The Reporting Person received the Exchange Shares in
exchange for the Reporting Person’s 25% membership interest in SafeStitch.
ITEM 4. Purpose of Transaction.
The acquisitions of Shares described in Item 3 to this 13D are hereby incorporated by
reference in this Item 4.
On December 11, 2002, the Issuer adopted a plan to wind down and cease all operations related
to its historical telecommunications business, which process it completed in December 2005. Upon
consummation of the Transactions, the Issuer adopted the business plan of SafeStitch, which is now
a wholly-owned subsidiary of the Issuer. The Issuer is now a developmental stage medical device
company focused on the development of medical devices that manipulate tissues for obesity,
gastroesophageal reflux disease (“GERD”), Barrett’s Esophagus, esophageal obstructions, upper
gastrointestinal bleeding, hernia formation and other intraperitoneal abnormalities through
endoscopic and minimally invasive surgery. To better reflect its new business, the Issuer presently
plans to change its name to Swan Medical Devices, Inc.
Additionally, pursuant to a corporate action signed by holders of more than two-thirds of the
issued and outstanding Shares, the structure of the Issuer’s board of directors (the “Board”) will
change. Presently, the Board is divided into three distinct classes, and the terms of the
directors in each such class
| |
|
|
|
|
|
|
|
|
|
|
CUSIP No. |
|
151167103 |
|
Page |
|
4 |
|
of |
|
6 |
expire in three consecutive years. At each annual meeting of stockholders, the successors to
the class of directors whose terms then expire are elected to hold office for new three-year terms
and until their successors have been elected and qualified. The Issuer plans to eliminate this
staggered arrangement with the effect that all directors on the Board comprise a single class;
therefore, all positions on the Board may be subject to an election in any given year. Also, one
new seat will be added to the Board.
Effective on the Closing Date, Stephen Katz, Lawrence Schoenberg, Joshua J. Angel and Dr.
Frost resigned as members of the Board, and the following persons were appointed by the remaining
members of the Board to serve as directors until the next meeting of stockholders, or until their
earlier removal, resignation or death: Dr. Kenneth Heithoff and Kevin Wayne as Class I directors;
Steven D. Rubin as a Class II director; and Jeffrey G. Spragens and Dr. Charles Filipi as Class III
directors.
Also in connection with the Transactions and pursuant to the stockholder action described
above, the Issuer’s Restated Certificate of Incorporation will be amended to increase the aggregate
number of shares of all classes of capital stock that the Issuer may issue from 35,000,000 to
250,000,000, which shall be composed of 225,000,000 shares of common stock, par value $0.001 per
share, and 25,000,000 shares of preferred stock, par value $0.01 per share.
The stockholder action referred to above will be effective 20 calendar days after the mailing
of an information statement on Schedule 14C to the Issuer’s stockholders.
ITEM 5. Interest in Securities of the Issuer.
| |
|
|
|
|
|
|
|
|
| |
|
Number of |
|
|
Percentage of |
|
| |
|
Outstanding Shares |
|
|
Outstanding Shares |
|
| Name and Title of Beneficial Owner |
|
Beneficially Owned |
|
|
of Common Stock(1) |
|
Dr. Charles Filipi |
|
2,814,092 |
|
|
|
17.5% |
|
|
|
|
| (1) |
|
The percentage of beneficial ownership is based upon 16,050,626 shares of Common Stock
outstanding. |
The Reporting Person’s response to Item 3 to this 13D is hereby incorporated by reference
in this Item 5. The Reporting Person’s responses to cover page Items 7 through 10 of this 13D are
hereby incorporated by reference in this Item 5.
ITEM 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
Pursuant to the Exchange Agreement, the Reporting Person entered into a lockup agreement
with respect to the Exchange Shares. Without the consent of the Board, the Reporting Person may
not sell or otherwise transfer the Exchange Shares, directly or indirectly, during the period
commencing on the Closing Date and ending on the date two years subsequent to the Closing Date.
ITEM 7. Material to be Filed as Exhibits
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
|
|
|
99.1
|
|
Share Transfer, Exchange and Contribution Agreement, dated July 25, 2007,
by and among Cellular Technical Services Company, Inc., SafeStitch LLC and the
members of SafeStitch LLC (incorporated herein by reference to Exhibit 2.1 to the
Current Report on Form 8-K filed by the Issuer on July 31, 2007). |
|
|
|
99.2
|
|
Amendment to Share Transfer, Exchange and Contribution Agreement
(incorporated herein by reference to Exhibit 2.2 to the Current Report on Form 8-K
filed by the Issuer on September 10, 2007). |
|
|
|
99.3
|
|
Form of Lockup Agreement (incorporated herein by reference to Exhibit 2.4
to the Current Report on Form 8-K filed by the Issuer on July 31, 2007). |
| |
|
|
|
|
|
|
|
|
|
|
CUSIP No. |
|
151167103 |
|
Page |
|
5 |
|
of |
|
6 |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.
| |
|
|
|
|
| |
|
|
| Dated: September 12, 2007 |
/s/ Dr. Charles Filipi
|
|
| |
Dr. Charles Filipi |
|
| |
|
|
| |
| |
|
|
|
|
|
|
|
|
|
|
CUSIP No. |
|
151167103 |
|
Page |
|
6 |
|
of |
|
6 |
EXHIBIT INDEX
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
|
|
|
99.1
|
|
Share Transfer, Exchange and Contribution Agreement, dated
July 25, 2007, by and among Cellular Technical Services
Company, Inc., SafeStitch LLC and the members of SafeStitch
LLC (incorporated herein by reference to Exhibit 2.1 to the
Current Report on Form 8-K filed by the Issuer on July 31,
2007) |
|
|
|
99.2
|
|
Amendment to Share Transfer, Exchange and Contribution
Agreement (incorporated herein by reference to Exhibit 2.2
to the Current Report on Form 8-K filed by the Issuer on
September 10, 2007). |
|
|
|
99.3
|
|
Form of Lockup Agreement (incorporated herein by reference
to Exhibit 2.4 to the Current Report on Form 8-K filed by
the Issuer on July 31, 2007). |